On social media, CURE® recently asked its readers to share if they sought a second opinion when discussing their cancer diagnosis and treatment. Here’s what some of them said.
Each week on Facebook, Twitter and Instagram, CURE® asks its readers to share their thoughts with a #CureConnect discussion question.
This past week, we asked: “Did you seek a second opinion when discussing your cancer diagnosis and treatment?”
Here’s what some of our readers shared:
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
FDA Prioritizes Review of Elahere in Ovarian Cancer
December 13th 2023The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
FDA Prioritizes Review of Elahere in Ovarian Cancer
December 13th 2023The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
2 Commerce Drive
Cranbury, NJ 08512